submit to the journals

SABCS Highlights

flipper_slider

Editor's Choice

Serena Nik Zainal discusses the key themes of this year’s plenary lectures and new developments in the field. 1. What were the key themes of this year’s plenary lecture "Advances in the Understanding of...

SABCS Highlights Videos

Giampaolo Bianchini from the IRCCS Ospendale San Raffaele, Milano, Lombardy, Italy, discusses why overall survival is considered the 'gold standard' endpoint for research into cancer agents and what this means for patients with metastatic breast cancer. 1. What is the clinical definition of...
John Crown talks to touchONCOLOGY about overall survival and what this means to patients with metastatic breast cancer. 1. Having extensive experience treating patients with metastatic breast cancer, what does extending life mean for them? (0:04) 2. Does life-extension remain an important...
Giampaolo Bianchini discusses overall survival as an endpoint for breast cancer research and how treatment regimens will change in the future. 1. What is the clinical definition of overall survival? (0:04) 2. Why is overall survival considered by many the ‘gold standard’ endpoint for research...
Serena Nik Zainal discusses the key themes of this year’s plenary lectures and new developments in the field. 1. What were the key themes of this year’s plenary lecture "Advances in the Understanding of Mutational Signatures in Human Cells"? (00:04) 2. What have been the key developments in...
Virginia G Kaklamani discusses endpoints of breast cancer trials and the potential for combination therapy. 1. What are the limitations as progression-free survival and overall survival as clinical endpoints in breast cancer trials? (00:04) 2. What other endpoints should be considered when...
At SABCS, Irene Wapnir talks to us about the CALOR trial and its likely impact on clinical practice. 1. Can you tell us a little about the rationale for and findings of the CALOR trial? (00:04) 2. How are the findings of the CALOR trial likely to impact on clinical practice? (07:04) 3. What do...
Irene Wapnir discusses locoregional recurrence, how it affects prognosis, and recommended treatment options. 1. How does locoregional recurrence of breast cancer affect prognosis? (00:04) 2. What are the current recommended treatment options for locoregional recurrence? (1:40) View Part 2...
Ruth O’Regan talks to us about the PI3K inhibition and the BELLE-2 trial investigating buparlisib. 1. What is the role of activation of the phosphatidylinositol-3 kinase (PI3K)/AKT pathway in hormonal therapy resistance? (00:04) 2. What were the findings of the BELLE-2 trial investigating...
Kathy Miller discusses the latest developments in the area of triple-negative breast cancer at SABCS 2017. 1. What are the most common misconceptions regarding triple-negative breast cancer? (00:04) 2. What are the most challenging aspects of treating triple-negative breast cancer? (01:04) 3....
Mothaffar Fahed Rimawi discusses treatment options for patients with HER2-positive metastatic breast cancer. 1. How far have we advanced in recent years in treating HER2-positive metastatic breast cancer? 2. What are the most important emerging neoadjuvant treatment options for HER2-positive...
In the second part of her interview, Eleni Andropoulou discusses emerging drivers and developments in breast cancer. 1. What are the most promising emerging molecular drivers of breast cancer? (00:04) 2. What new developments do you anticipate in 2018? (03:52) 3. What do you expect to be the...
Eleni Andreopoulou explains the concept and limitations of precision medicine in breast cancer. 1. Could you explain the concept of precision medicine in breast oncology? (00:04) 2. What are the current limitations of this approach? (01:21) View Part 2 here. Speaker disclosures: Eleni...